The complementary expertise within the team provides an opportunity for PEP-Therapy to streamline all stages of drug development from licensing and partnerships, design of new CP&IPs through preclinical studies and clinical trials.
• Antoine Prestat - Founder & CEO
Engineering degree in biology combined with an MBA. 15 years in Technology Transfer Offices and as an adviser and a business developer for biotech companies.
• Jennifer Sengenès, PhD - Head of strategy and development
Engineering degree in chemistry, PhD in molecular biology combined with an MBA. 9 years in project management and financing, and start-ups development.
• Didier Decaudin, MD, PhD - Founder and scientific advisor
Department of Medical Oncology at Institut Curie & Head of the Laboratory of Preclinical Investigation (LIP) in the Department of Translational Research.
• Fariba Némati, PhD - Founder and scientific advisor
Research Engineer in the LIP at Institut Curie. Expertise in Patient-Derived Xenografts (PDXs) and pharmacology.
• Angelita Rebollo, PhD - Founder and scientific advisor
Research Director at Centre d’Immunologie et des Maladies Infectieuses (CIMI, Inserm/UPMC/CNRS). Expertise in apoptosis and in the design of Cell Penetrating & Interfering Peptides.
Strategic Advisory Board
• Philippe Tramoy
Investment Director of Quadrivium 1 seed fund at Seventure Partners. Former business development manager in Europe and Israel within the biotechnology market at Rhodia Corporate, Rhodia Chirex, and Rhodia Pharma Solutions. Founder and former Managing Partner of CBDMT, a Market & Business Intelligence company.
• Bernard Majoie, PhD
Former Scientific Director and then Chairman and Chief Executive Officer of Laboratoires Fournier. Founding Chairman of la Fondation Fournier-Majoie pour l'Innovation (FFMI). He now invests in high-potential projects led by committed researcher-entrepreneurs.
• Jean-Loup Romet Lemonne, MD
Senior Advisor Global Development at Institut Pasteur, Founder and former CEO of IDM Pharma, Inc. (NASDAQ listed company, now part of Takeda Oncology).